Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. Stephanie Meier , Eline A J Willemse , Sabine Schaedelin , Johanna Oechtering , Johannes Lorscheider , Lester Melie-Garcia , Alessandro Cagol , Muhamed Barakovic , Riccardo Galbusera , Suvitha Subramaniam , Christian Barro , Ahmed Abdelhak , Simon Thebault , Lutz Achtnichts , Patrice Lalive , Stefanie Müller , Caroline Pot , Anke Salmen , Giulio Disanto , Chiara Zecca , Marcus D'Souza , Annette Orleth , Michael Khalil , Arabella Buchmann , Renaud Du Pasquier , Özgür Yaldizli , Tobias Derfuss , Klaus Berger , Marco Hermesdorf , Heinz Wiendl , Fredrik Piehl , Marco Battaglini , Urs Fischer , Ludwig Kappos , Claudio Gobbi , Cristina Granziera , Claire Bridel , David Leppert , Aleksandra Maleska Maceski , Pascal Benkert , Jens Kuhle JAMA neurology(2023)
摘要
Results of this cohort study suggest that sGFAP is a prognostic biomarker for future PIRA and revealed its complementary potential next to sNfL. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.
更多 查看译文
关键词
multiple sclerosis, neurofilament light chain, biomarker, disease progression
AI 理解论文
溯源树
样例